E Solau-Gervais

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. ncbi request reprint Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody
    E Solau-Gervais
    Service de Rhumatologie, Centre Hospitalier Regional et Universitaire de Lille, 59037 Lille Cedex, France
    Rheumatology (Oxford) 45:1121-4. 2006
  2. ncbi request reprint Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study
    Elisabeth Solau-Gervais
    Department of Rheumatology, Lille University Hospital, Lille, France
    J Rheumatol 33:1760-5. 2006
  3. ncbi request reprint Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis
    X Puechal
    Department of Rheumatology, Le Mans General Hospital, Le Mans, France
    Ann Rheum Dis 67:880-4. 2008
  4. ncbi request reprint Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis
    E Solau-Gervais
    Department of Rheumatology, Roger Salengro Hospital, Lille, France
    Scand J Rheumatol 36:373-7. 2007
  5. ncbi request reprint Axial osteomalacia with sacroiliitis and moderate phosphate diabetes: report of a case
    B Cortet
    Department of Rheumatology, University Hospital of Lille, France
    Clin Exp Rheumatol 18:625-8. 2000
  6. ncbi request reprint The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome
    E Solau-Gervais
    Department of Rheumatology, Lille University Hospital, Lille, France
    Rheumatology (Oxford) 45:339-42. 2006
  7. doi request reprint A functional haplotype of PADI4 gene in rheumatoid arthritis: positive correlation in a French population
    Frédérique Gandjbakhch
    Department of Rheumatology, Lille University Hospital, Lille, France
    J Rheumatol 36:881-6. 2009
  8. doi request reprint Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody
    E Solau-Gervais
    Service de Rhumatologie, Centre Hospitalier Regional et Universitaire de Lille, 59037 Lille Cedex, France
    Rheumatology (Oxford) 45:1121-4. 2006
    ..The objective of this retrospective study was to assess the response to treatment in RA patients who had received the three anti-TNF-alpha agents, namely infliximab, etanercept and adalimumab...
  2. ncbi request reprint Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study
    Elisabeth Solau-Gervais
    Department of Rheumatology, Lille University Hospital, Lille, France
    J Rheumatol 33:1760-5. 2006
    ....
  3. ncbi request reprint Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis
    X Puechal
    Department of Rheumatology, Le Mans General Hospital, Le Mans, France
    Ann Rheum Dis 67:880-4. 2008
    ..To assess anti-tumour necrosis factor (anti-TNF) agents in patients with refractory systemic rheumatoid vasculitis (SRV)...
  4. ncbi request reprint Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis
    E Solau-Gervais
    Department of Rheumatology, Roger Salengro Hospital, Lille, France
    Scand J Rheumatol 36:373-7. 2007
    ..4.22.1) and L (EC 3.4.22.15), calpain (EC 3.4.22.17), and dipeptidyl peptidase (EC 3.4.14.5 or DPP IV or CD26) in synovial membrane from patients with rheumatoid arthritis (RA), osteoarthritis (OA), and post-traumatic joint injury (PT)...
  5. ncbi request reprint Axial osteomalacia with sacroiliitis and moderate phosphate diabetes: report of a case
    B Cortet
    Department of Rheumatology, University Hospital of Lille, France
    Clin Exp Rheumatol 18:625-8. 2000
    ..The patient was treated with calcitriol which was promptly discontinued due to gastrointestinal symptoms and replaced by calcidiol without any significant effect on the low back pain...
  6. ncbi request reprint The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome
    E Solau-Gervais
    Department of Rheumatology, Lille University Hospital, Lille, France
    Rheumatology (Oxford) 45:339-42. 2006
    ..Pamidronate has recently been used in SAPHO syndrome due to its anti-osteoclastic effect. The aim of this study is to determine the usefulness of bone remodelling markers for determining the efficacy of pamidronate treatment...
  7. doi request reprint A functional haplotype of PADI4 gene in rheumatoid arthritis: positive correlation in a French population
    Frédérique Gandjbakhch
    Department of Rheumatology, Lille University Hospital, Lille, France
    J Rheumatol 36:881-6. 2009
    ....
  8. doi request reprint Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...